[PBBANK] YoY Cumulative Quarter Result on 30-Sep-2019 [#3]

Announcement Date
07-Nov-2019
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2019
Quarter
30-Sep-2019 [#3]
Profit Trend
QoQ- 49.68%
YoY- -1.9%
View:
Show?
Cumulative Result
30/09/22 30/09/21 30/09/20 30/09/19 30/09/18 30/09/17 30/09/16 CAGR
Revenue 15,364,016 14,763,875 15,387,170 16,780,610 16,409,767 15,507,624 15,018,657 0.37%
PBT 6,310,108 5,560,414 4,810,343 5,311,651 5,311,446 5,160,435 4,761,321 4.80%
Tax -1,861,492 -1,229,121 -1,043,458 -1,152,432 -1,071,575 -1,118,821 -993,155 11.03%
NP 4,448,616 4,331,293 3,766,885 4,159,219 4,239,871 4,041,614 3,768,166 2.80%
-
NP to SH 4,405,822 4,275,700 3,723,743 4,105,691 4,185,255 3,984,567 3,724,093 2.84%
-
Tax Rate 29.50% 22.10% 21.69% 21.70% 20.17% 21.68% 20.86% -
Total Cost 10,915,400 10,432,582 11,620,285 12,621,391 12,169,896 11,466,010 11,250,491 -0.50%
-
Net Worth 49,213,866 46,991,345 46,081,370 42,604,914 39,800,070 35,908,418 32,826,175 6.97%
Dividend
30/09/22 30/09/21 30/09/20 30/09/19 30/09/18 30/09/17 30/09/16 CAGR
Div 2,329,283 1,455,801 - 1,281,105 1,242,284 1,042,603 1,003,988 15.05%
Div Payout % 52.87% 34.05% - 31.20% 29.68% 26.17% 26.96% -
Equity
30/09/22 30/09/21 30/09/20 30/09/19 30/09/18 30/09/17 30/09/16 CAGR
Net Worth 49,213,866 46,991,345 46,081,370 42,604,914 39,800,070 35,908,418 32,826,175 6.97%
NOSH 19,410,691 19,410,691 3,882,138 3,882,138 3,882,138 3,882,138 3,882,138 30.75%
Ratio Analysis
30/09/22 30/09/21 30/09/20 30/09/19 30/09/18 30/09/17 30/09/16 CAGR
NP Margin 28.95% 29.34% 24.48% 24.79% 25.84% 26.06% 25.09% -
ROE 8.95% 9.10% 8.08% 9.64% 10.52% 11.10% 11.34% -
Per Share
30/09/22 30/09/21 30/09/20 30/09/19 30/09/18 30/09/17 30/09/16 CAGR
RPS 79.15 76.06 396.36 432.25 422.70 401.60 388.93 -23.29%
EPS 22.70 22.03 95.92 105.76 108.17 103.19 96.44 -21.41%
DPS 12.00 7.50 0.00 33.00 32.00 27.00 26.00 -12.08%
NAPS 2.5354 2.4209 11.8701 10.9746 10.2521 9.2991 8.5009 -18.25%
Adjusted Per Share Value based on latest NOSH - 3,882,138
30/09/22 30/09/21 30/09/20 30/09/19 30/09/18 30/09/17 30/09/16 CAGR
RPS 79.13 76.04 79.25 86.42 84.51 79.87 77.35 0.37%
EPS 22.69 22.02 19.18 21.15 21.56 20.52 19.18 2.83%
DPS 12.00 7.50 0.00 6.60 6.40 5.37 5.17 15.05%
NAPS 2.5346 2.4202 2.3733 2.1943 2.0498 1.8494 1.6906 6.97%
Price Multiplier on Financial Quarter End Date
30/09/22 30/09/21 30/09/20 30/09/19 30/09/18 30/09/17 30/09/16 CAGR
Date 30/09/22 30/09/21 30/09/20 30/09/19 28/09/18 29/09/17 30/09/16 -
Price 4.23 4.07 15.70 20.08 25.00 20.44 19.82 -
P/RPS 5.34 5.35 3.96 4.65 5.91 5.09 5.10 0.76%
P/EPS 18.64 18.48 16.37 18.99 23.19 19.81 20.55 -1.61%
EY 5.37 5.41 6.11 5.27 4.31 5.05 4.87 1.64%
DY 2.84 1.84 0.00 1.64 1.28 1.32 1.31 13.75%
P/NAPS 1.67 1.68 1.32 1.83 2.44 2.20 2.33 -5.39%
Price Multiplier on Announcement Date
30/09/22 30/09/21 30/09/20 30/09/19 30/09/18 30/09/17 30/09/16 CAGR
Date 30/11/22 29/11/21 27/11/20 07/11/19 25/10/18 26/10/17 20/10/16 -
Price 4.50 3.96 18.60 19.86 24.90 20.48 19.80 -
P/RPS 5.69 5.21 4.69 4.59 5.89 5.10 5.09 1.87%
P/EPS 19.83 17.98 19.39 18.78 23.10 19.85 20.53 -0.57%
EY 5.04 5.56 5.16 5.33 4.33 5.04 4.87 0.57%
DY 2.67 1.89 0.00 1.66 1.29 1.32 1.31 12.59%
P/NAPS 1.77 1.64 1.57 1.81 2.43 2.20 2.33 -4.47%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment